Prices delayed by at least 15 minutes | Print


iCAD (ICAD)

Common Shares
Sell: $1.42|Buy: $1.5|Change: 0.03 (2.13%)

Open 

$1.4301


Previous close 

$1.41


Trade high 

$1.4585


Volume 

79,703


Year high 

$3.97


Year low 

$1.05


Dividend yield 

-


Market capitalisation 

$37.97 mn


P/E ratio 

-


ISIN 

US44934S2068


This share can be held in a Dealing accountISALifetime ISAJISASIPP

Share price

Performance 08/05/2024

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann


Total return (%)
iCAD+ 2.13
More...

Company profile

icad Inc is a medical technology company providing cancer detection and therapy solutions. The Company operates in one segment: Detection. The Detection segment include advanced image analysis and workflow solutions that enable healthcare professionals to serve patients by identifying pathologies, comprehensive range of high-performance, Artificial Intelligence and Computer-Aided Detection (CAD) systems and workflow solutions for 2D and 3D mammography, Magnetic Resonance Imaging and Computed Tomography. The company geographically operates in France, Belgium, Italy, Germany, Switzerland and All other.

Sector 

Healthcare


AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2024 AJ Bell. All rights reserved.